|
1
|
Costabel U: The changing treatment
landscape in idiopathic pulmonary fibrosis. Eur Respir Rev.
24:65–68. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Renzoni E, Srihari V and Sestini P:
Pathogenesis of idiopathic pulmonary fibrosis: Review of recent
findings. F1000Prime Rep. 6:692014. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kraan JW, van den Blink B, van den Toorn
LM, Bresser P, van Beek FT, Grutters JC and Wijsenbeek MS:
Idiopathic pulmonary fibrosis: New insights. Ned Tijdschr Geneeskd.
159:A81482015.(In Dutch). PubMed/NCBI
|
|
4
|
Mezni I, Galichon P, Bacha MM, Sfar I,
Hertig A, Goucha R, Xu-Dubois YC, Abderrahim E, Gorgi Y, Rondeau E
and Abdallah TB: The epithelial-mesenchymal transition and fibrosis
of the renal transplant. Med Sci (Paris). 31:68–74. 2015.(In
French). View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gonzalez DM and Medici D: Signaling
mechanisms of the epithelial-mesenchymal transition. Sci Signal.
7:re82014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Long H, Xiang T, Qi W, Huang J, Chen J, He
L, Liang Z, Guo B, Li Y, Xie R and Zhu B: CD133+ ovarian cancer
stem-like cells promote non-stem cancer cell metastasis via CCL5
induced epithelial-mesenchymal transition. Oncotarget. 6:5846–5859.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park JH and Yoon J: Schizandrin inhibits
fibrosis and epithelial-mesenchymal transition in transforming
growth factor-β1-stimulated AML12 cells. Int Immunopharmacol.
25:276–284. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
He L, Lou W, Ji L, Liang W, Zhou M, Xu G,
Zhao L, Huang C, Li R, Wang H, et al: Serum response factor
accelerates the high glucose-induced Epithelial-to-Mesenchymal
Transition (EMT) via snail signaling in human peritoneal
mesothelial cells. PLoS One. 9:e1085932014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim KK, Kugler MC, Wolters PJ, Robillard
L, Galvez MG, Brumwell AN, Sheppard D and Chapman HA: Alveolar
epithelial cell mesenchymal transition develops in vivo during
pulmonary fibrosis and is regulated by the extracellular matrix.
Proc Natl Acad Sci USA. 103:13180–13185. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Namba T, Tanaka KI, Ito Y, Hoshino T,
Matoyama M, Yamakawa N, Isohama Y, Azuma A and Mizushima T:
Induction of EMT-like phenotypes by an active metabolite of
leflunomide and its contribution to pulmonary fibrosis. Cell Death
Differ. 17:1882–1895. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hong RT, Xu JM and Mei Q: Melatonin
ameliorates experimental hepatic fibrosis induced by carbon
tetrachloride in rats. World J Gastroenterol. 15:1452–1458. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Milara J, Navarro R, Juan G, Peiró T,
Serrano A, Ramón M, Morcillo E and Cortijo J:
Sphingosine-1-phosphate is increased in patients with idiopathic
pulmonary fibrosis and mediates epithelial to mesenchymal
transition. Thorax. 67:147–156. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou CF, Zhou DC, Zhang JX, Wang F, Cha
WS, Wu CH and Zhu QX: Bleomycin-induced epithelial-mesenchymal
transition in sclerotic skin of mice: Possible role of oxidative
stress in the pathogenesis. Toxicol Appl Pharmacol. 277:250–258.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cho YA, Noh K, Jue SS, Lee SY and Kim EC:
Melatonin promotes hepatic differentiation of human dental pulp
stem cells: Clinical implications for the prevention of liver
fibrosis. J Pineal Res. 58:127–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Drobnik J, Slotwinska D, Olczak S, Tosik
D, Pieniazek A, Matczak K, Koceva-Chyla A and Szczepanowska A:
Pharmacological doses of melatonin reduce the glycosaminoglycan
level within the infarcted heart scar. J Physiol Pharmacol.
62:29–35. 2011.PubMed/NCBI
|
|
16
|
Zhao H, Wu QQ, Cao LF, Qing HY, Zhang C,
Chen YH, Wang H, Liu RY and Xu DX: Melatonin inhibits endoplasmic
reticulum stress and epithelial-mesenchymal transition during
bleomycin-induced pulmonary fibrosis in mice. PLoS One.
9:e972662014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
National Clinical Guideline Centre (UK), .
Diagnosis and management of suspected idiopathic pulmonary
fibrosis: Idiopathic pulmonary fibrosis [Internet]. National
Institute for Health and Care Excellence: Clinical Guidelines.
2013.
|
|
18
|
Inomata M, Nishioka Y and Azuma A:
Nintedanib: Evidence for its therapeutic potential in idiopathic
pulmonary fibrosis. Core Evid. 10:89–98. 2015.PubMed/NCBI
|
|
19
|
Aravena C, Labarca G, Venegas C, Arenas A
and Rada G: Pirfenidone for idiopathic pulmonary fibrosis: A
systematic review and meta-analysis. PLoS One. 10:e01361602015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Johansson J, Tabor V, Wikell A, Jalkanen S
and Fuxe J: TGF-β1-Induced epithelial-mesenchymal transition
promotes monocyte/macrophage properties in breast cancer cells.
Front Oncol. 5:32015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu Y, Ginther C, Kim J, Mosher N, Chung S,
Slamon D and Vadgama JV: Expression of Wnt3 activates Wnt/β-catenin
pathway and promotes EMT-like phenotype in trastuzumab-resistant
HER2-overexpressing breast cancer cells. Mol Cancer Res.
10:1597–1606. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Borthwick LA, Gardner A, De Soyza A, Mann
DA and Fisher AJ: Transforming growth factor-β1 (TGF-β1) driven
epithelial to mesenchymal transition (EMT) is accentuated by tumour
necrosis factor α (TNFα) via crosstalk between the SMAD and NF-κB
pathways. Cancer Microenviron. 5:45–57. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Noth I, Zhang Y, Ma SF, Flores C, Barber
M, Huang Y, Broderick SM, Wade MS, Hysi P, Scuirba J, et al:
Genetic variants associated with idiopathic pulmonary fibrosis
susceptibility and mortality: A genome-wide association study.
Lancet Respir Med. 1:309–317. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Singh VK, George M Patricia and Gries CJ:
Pulmonary hypertension is associated with increased post-lung
transplant mortality risk in patients with chronic obstructive
pulmonary disease. J Heart Lung Transplant. 34:424–429. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tzouvelekis A, Bonella F and Spagnolo P:
Update on therapeutic management of idiopathic pulmonary fibrosis.
Ther Clin Risk Manag. 11:359–370. 2015.PubMed/NCBI
|
|
26
|
Choi SH, Hong ZY, Nam JK, Lee HJ, Jang J,
Yoo RJ, Lee YJ, Lee CY, Kim KH, Park S, et al: A hypoxia-induced
vascular endothelial-to-mesenchymal transition in development of
radiation-induced pulmonary fibrosis. Clin Cancer Res.
21:3716–3726. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Longatti P, Perin A, Rizzo V, Comai S,
Giusti P and Costa CV: Ventricular cerebrospinal fluid melatonin
concentrations investigated with an endoscopic technique. J Pineal
Res. 42:113–118. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rodella LF, Favero G, Foglio E, Rossini C,
Castrezzati S, Lonati C and Rezzani R: Vascular endothelial cells
and dysfunctions: Role of melatonin. Front Biosci (Elite Ed).
5:119–129. 2013.PubMed/NCBI
|
|
29
|
Li JG, Lin JJ, Wang ZL, Cai WK, Wang PN,
Jia Q, Zhang AS, Wu GY, Zhu GX and Ni LX: Melatonin attenuates
inflammation of acute pulpitis subjected to dental pulp injury. Am
J Transl Res. 7:66–78. 2015.PubMed/NCBI
|
|
30
|
Li H, Li Y, Liu D and Liu J: LPS promotes
epithelial-mesenchymal transition and activation of TLR4/JNK
signaling. Tumour Biol. 35:10429–10435. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim YM and Cho M: Activation of NADPH
oxidase subunit NCF4 induces ROS-mediated EMT signaling in HeLa
cells. Cell Signal. 26:784–796. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Duan W, Yang Y, Yi W, Yan J, Liang Z, Wang
N, Li Y, Chen W, Yu S, Jin Z and Yi D: New role of JAK2/STAT3
signaling in endothelial cell oxidative stress injury and
protective effect of melatonin. PLoS One. 8:e579412013. View Article : Google Scholar : PubMed/NCBI
|
